How this company measures up on the fundamentals that matter
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of haza
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $149 against a fair value of $270, a 45% discount. Fails ethical screen (Debt ratio). Ranks better than 70% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-07 | ROQUE VITOR | Chief Financial Officer | 1,721 | — | |
| 2026-04-27 | FELD MICHAEL | Officer | 74 | $11,244 | |
| 2026-03-26 | FELD MICHAEL | Officer | 75 | $11,762 | |
| 2026-03-16 | MINNIX LANESHA | General Counsel | 7,492 | — | |
| 2026-03-02 | SPIKNER PAMELA L | Officer | 931 | — | |
| 2026-03-02 | ROQUE VITOR | Chief Financial Officer | 931 | — | |
| 2026-02-26 | FELD MICHAEL | Officer | 75 | $13,638 | |
| 2026-02-18 | SCOTT BERTRAM LEE | Director | 953 | $174,027 | |
| 2026-01-27 | RING TIMOTHY M | Director | 1,098 | — | |
| 2026-01-27 | WRIGHT JACQUELINE | Director | 1,098 | — |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Sale | 15K–50K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2025-09-30